Publicaciones en colaboración con investigadores/as de Hospital de Cabueñes (23)

2023

  1. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  2. The Risk of Developing Disabling Crohn's Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making

    Digestive Diseases, Vol. 41, Núm. 6, pp. 879-889

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  3. Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study

    Journal of Crohn's & colitis, Vol. 16, Núm. 9, pp. 1428-1435

2021

  1. European registry on helicobacter pylori management: Effectiveness of first and second-line treatment in Spain

    Antibiotics, Vol. 10, Núm. 1, pp. 1-15

  2. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

2020

  1. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg)

    Helicobacter, Vol. 25, Núm. 5

  2. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 89-98

2019

  1. Hemostatic spray powder TC-325 for GI bleeding in a nationwide study: survival and predictors of failure via competing risks analysis

    Gastrointestinal Endoscopy, Vol. 90, Núm. 4, pp. 581-590.e6

2018

  1. Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279

2017

  1. Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease

    Journal of Crohn's and Colitis, Vol. 11, Núm. 7, pp. 792-800

2016

  1. Outcomes of medical and surgical therapy for entero-urinary fistulas in Crohn's disease

    Journal of Crohn's and Colitis, Vol. 10, Núm. 6, pp. 657-662

2014

  1. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment

    Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293

2013

  1. Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients

    Inflammatory Bowel Diseases, Vol. 19, Núm. 7, pp. 1404-1410

  2. Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era

    Alimentary Pharmacology and Therapeutics, Vol. 38, Núm. 7, pp. 752-760

2012

  1. Long-term durability of response to adalimumab in Crohn's disease

    Inflammatory Bowel Diseases, Vol. 18, Núm. 4, pp. 685-690

2011

  1. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

    Alimentary Pharmacology and Therapeutics, Vol. 33, Núm. 3, pp. 340-348

2010

  1. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy

    Gut, Vol. 59, Núm. 10, pp. 1340-1346

2008

  1. Recomendaciones de actuación en pacientes con enfermedad de Crohn que empiezan tratamiento con adalimumab: Una guía rápida

    Gastroenterologia y Hepatologia, Vol. 31, Núm. 10, pp. 693-697